Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 25, 2023 08:00 ET | Source: BioAtla, Inc.

BioAtla to Announce Second Quarter 2023 Financial Results and Provide Business Highlights on August 1, 2023

SAN DIEGO, July 25, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
June 26, 2023 08:00 ET | Source: BioAtla, Inc.

BioAtla Added to Membership of U.S. Small-Cap Russell 2000® Index

SAN DIEGO, June 26, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
May 31, 2023 08:00 ET | Source: BioAtla, Inc.

BioAtla to Participate in the Jefferies Healthcare Conference

SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
May 11, 2023 16:01 ET | Source: BioAtla, Inc.

BioAtla Reports First Quarter 2023 Financial Results and Highlights Recent Progress

Advancing CAB-AXL BA3011 in ongoing sarcoma Phase 2 studies including a potentially registrational study in Undifferentiated Pleomorphic Sarcoma (UPS); expect Leiomyosarcoma (LMS) cohort readout in...
May 08, 2023 16:05 ET | Source: BioAtla, Inc.

BioAtla to Participate in the JMP Securities Life Sciences Conference

SAN DIEGO, May 08, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
May 04, 2023 08:00 ET | Source: BioAtla, Inc.

BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023

SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
March 23, 2023 16:05 ET | Source: BioAtla, Inc.

BioAtla Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress

- Cleared dose-limiting toxicity (DLT) observation period with more frequent, dose-intensive regimen of CAB-AXL BA3011; anticipated leiomyosarcoma (LMS) cohort readout in 2H23 - Initiated the...
March 16, 2023 08:00 ET | Source: BioAtla, Inc.

BioAtla to Announce Fourth Quarter and Full-Year 2022 Financial Results and Provide Business Highlights

SAN DIEGO, March 16, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
February 27, 2023 08:07 ET | Source: BioAtla, Inc.

BioAtla Announces Change in Executive Leadership

SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
February 23, 2023 08:00 ET | Source: BioAtla, Inc.

BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3182, a CAB-EpCAMxCAB-CD3 Bispecific T-Cell Engager for the Treatment of Advanced Adenocarcinoma

Following the IND clearance, the Company is advancing into a Phase 1 clinical study Potentially addressing most common subtypes of adenocarcinoma including colon, lung, breast, pancreas, and prostate...